ArticlePloS one2025

First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis.

Huijuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.